Lipid Therapeutics licenses rights to new drug compound for intestinal inflammation to Nestlé Health Science
Lipid Therapeutics on Wednesday said it has signed a licensing agreement with Nestlé Health Science for exclusive rights to Lipid's LT-02 compound (phosphatidylcholine) to treat inflammatory condition of the large intestine, ulcerative colitis (UC).
Under the terms of the agreement, the German company will receive an upfront fee, milestones payments and royalties on net sales. However, no specific financial details were disclosed. Nestlé Health Science will be responsible for developing and marketing LT-02 worldwide, except in Europe and Australia.
The LT-02 compound is a novel barrier function therapy for patients with mild-to-moderate UC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze